| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 411.5 | 334.2 |
| Profit before tax | -12.4 | -81.2 |
| Net income | -14.9 | -80.0 |
| EPS (diluted, $ a share) | $-0.08 | $-0.46 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +23.1% |
|---|---|
| Operating margin | -13.8% |
10-Q filed with the SEC, NASDAQ: TEM. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Tempus AI, Inc.: key numbers
- Share price
- $64.76Close, Nov 16
- Sector
- Technology
- Industry
- Services-Computer Programming, Data Processing, Etc.SIC 7370
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Tempus AI, Inc.
All →Tempus AI Director David R. Epstein Sells $27.5K of Stock
David R. Epstein, Director, sold 370 shares of Tempus AI, Inc. at $74.29 a share, worth $27.5K in total on Nov 2, 2026. Shares held after the trade: 30,474 (-1.2%).
- Value
- $27.5K
- Shares
- 370
- Price
- $74.29
- Role
- Director
- Holding change
- -1.2%
- Trade date
- Nov 2, 2026
Tempus AI Financial Results
Tempus AI reported record Q3 2026 revenue of $411.5 million, a 23% year-over-year increase driven by strong growth in its Oncology and Data & Applications segments. The company narrowed its net loss to $14.9 million and raised its full-year 2026 revenue guidance to a range of $1.60 billion to $1.605 billion.
- Term
- Q3 2026
“Q3 was another record quarter, as we delivered $411.5 million of revenue, led by accelerating unit growth of 32% in our oncology business and increasing momentum of 33% revenue growth in Data & Applications. These results reinforce the durability of our model as our best-in-class diagnostic platform enhances our data and AI offerings, distinguishes our business from our many competitors, and helps drive our performance quarter after quarter.”
Eric Lefkofsky, founder and CEO of Tempus
Tempus AI CEO and Chairman Eric P. Lefkofsky Sells $17.6M of Stock
Eric P. Lefkofsky, CEO and Chairman, sold 250,000 shares of Tempus AI, Inc. at $67.36 to $72.31 a share (average $70.36) in 24 transactions, worth $17.6M in total on Oct 27, 2026. Shares held after the trade: 50,000 (-20.9%).
- Value
- $17.6M
- Shares
- 250,000
- Average price
- $70.36
- Role
- CEO and Chairman
- Holding change
- -20.9%
- Trade date
- Oct 27, 2026
Tempus AI Licensing Deal with Bristol-Myers Squibb Company Worth $192M
Tempus AI entered into a series of agreements with Bristol-Myers Squibb (BMS) and Pathos AI to expand the use of its de-identified multimodal real-world data and analysis tools. The deal provides for aggregate cash payments to Tempus of $192.5 million over approximately five years, including $137.5 million for oncology data services to BMS and $55 million for neurology data and agentic tools to Pathos to support BMS's therapeutic development.
- Value
- $192M
- Counterparty
- Bristol-Myers Squibb Company
- Term
- 5 years
Tempus AI CEO and Chairman Eric P. Lefkofsky Sells $19.4M of Stock
Eric P. Lefkofsky, CEO and Chairman, sold 249,976 shares of Tempus AI, Inc. at $76.57 to $78.86 a share (average $77.47) in 15 transactions, worth $19.4M in total on Sep 22, 2026. Shares held after the trade: 804,246 (-0.5%).
- Value
- $19.4M
- Shares
- 249,976
- Average price
- $77.47
- Role
- CEO and Chairman
- Holding change
- -0.5%
- Trade date
- Sep 22, 2026
Tempus AI EVP, CLO Andrew Polovin Sells $221K of Stock
Andrew Polovin, EVP, CLO, sold 2,951 shares of Tempus AI, Inc. at $75.00 a share, worth $221K in total on Sep 17, 2026. Shares held after the trade: 135,189 (-2.1%).
- Value
- $221K
- Shares
- 2,951
- Price
- $75.00
- Role
- EVP, CLO
- Holding change
- -2.1%
- Trade date
- Sep 17, 2026